This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Bacillus calmette-guerin substrain tice live antigen is a live attenuated vaccine against Mycobacterium bovis.

Brand Names
BCG Vaccine, Tice Bcg
Generic Name
Bacillus calmette-guerin substrain tice live antigen
DrugBank Accession Number
DB10343
Background

Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • BCG, Live, Tice Strain

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Altretamine.
AmantadineThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Amantadine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bcg VaccineInjection, powder, lyophilized, for solution50 mg/1PercutaneousMerck Sharp & Dohme Corp.1989-06-21Not applicableUS flag
OncoticePowder, for solution50 mg/1IntravesicalMerck Ltd.1995-12-31Not applicableCanada flag
Tice BcgPowder, for suspension50 mg/50mLIntravesicalMerck Sharp & Dohme Corp.1990-08-24Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2XQ558L16Z
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910522
RxNav
221050

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentStage 0 Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Urothelial Carcinoma1
3Not Yet RecruitingTreatmentBladder Cancer, Cancer / Bladder transitional cell carcinoma / Neoplasms Recurrence / Non-Invasive Bladder Urothelial Carcinoma / Recurrent Bladder Cancer / Urothelial Carcinoma Recurrent1
3RecruitingTreatmentBladder Cancer, Cancer3
3RecruitingTreatmentHigh-Risk Non-Muscle-Invasive Bladder Cancer1
3WithdrawnPreventionCoronavirus Disease 2019 (COVID‑19)1
2RecruitingSupportive CareBladder Urothelial Carcinoma In Situ / Stage 0a Bladder Cancer AJCC v8 / Stage 0is Bladder Cancer AJCC v8 / Stage I Bladder Cancer AJCC v8 / Superficial Bladder Urothelial Carcinoma / Urothelial Carcinoma Bladder Recurrent1
2, 3Not Yet RecruitingTreatmentMetastatic Cutaneous Melanoma1
1Active Not RecruitingTreatmentRecurrent Bladder Carcinoma / Stage 0a Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Cancer1
1CompletedTreatmentBladder Cancer, Cancer1
1CompletedTreatmentTransitional Cell Carcinoma of Bladder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionPercutaneous50 mg/1
Injection, powder, for suspensionIntravesical50 mg
Powder, for solutionIntravesical50 mg/1
Powder, for suspensionIntravesical50 mg/50mL
Injection, powder, lyophilized, for suspension50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:03 / Updated at October 26, 2021 21:40